Hasil Pencarian - Filip Deforce
Anda harus masuk terlebih dahulu
- Menampilkan 1 - 3 hasil dari 3
-
1
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, v... oleh Martin Demarchi, Pierre Coliat, Kristi Mclendon, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Ang, Litha Jaison, Filip Deforce, Marie Paule Derde, Michael Jinwoo Kim, Lisa Soyeon Park, Alexandre Detappe, Xavier Pivot
Diterbitkan 2021-08-01Dapatkan teks lengkap
Artikel -
2
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting oleh Xavier Pivot, Alexey Georgievitch Manikhas, Volodymyr Shamrai, Giorgi Dzagnidze, Hwoei Fen Soo Hoo, Viriya Kaewkangsadan, Fausto Petrelli, Cristian Villanueva, Jamie Kim, Sumita Pradhan, Litha Jaison, Peggy Feyaerts, Leonard Kaufman, Marie-Paule Derde, Filip Deforce, David G. Cox
Diterbitkan 2023-01-01Dapatkan teks lengkap
Artikel -
3
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. oleh Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot
Diterbitkan 2021-01-01Dapatkan teks lengkap
Artikel